Drugs / ALVAC(2)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00613509 | Jun 2008 → Apr 2010 | cancer, melanoma | Sanofi Pasteur, a Sanofi Company | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC(2) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00613509 ↗ |
| Modality | Vaccine | “multi-antigen therapeutic vaccine” NCT00613509 ↗ |